Harrow Health Inc logo

Harrow Health Inc(HROW)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$30.41
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HROW

11/20/2026: HROW (1-star) is currently NOT-A-BUY. Pass it for now.

Harrow Health is a specialized pharmaceutical stock focused on the US eye-care sector through its proprietary branded therapies and ImprimisRx compounding network. The company's main strengths lie in its rapid top-line revenue growth and established relationships with ophthalmology clinics and surgical centers. Its primary investment story centers on scaling flagship products like VEVYE and IHEEZO to capture market share in dry eye and surgical care. However, investors must weigh key risks including persistent net losses, high debt leverage, and intense competition from larger industry players. The stock suits growth-oriented investors willing to tolerate volatility while monitoring progress toward sustained profitability and operational cash flow generation.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company has delivered rapid multi-year revenue expansion driven by portfolio scaling and new product launches.
Momentum investorStrong fit while signal remains positiveThe stock attracts technical interest during periods of strong quarterly revenue beats and upgraded forward guidance.
Value investorWeak fitHarrow remains unprofitable on a GAAP basis and trades on growth expectations rather than traditional earnings multiples.
Dividend investorWeak fitThe company does not pay dividends, choosing instead to reinvest capital into commercial growth.
Low-risk investorWeak fitHigh share price volatility, debt leverage, and lack of consistent net income expose investors to significant downside risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp price swings reacting to quarterly earnings reports, guidance adjustments, and market sentiment.
Valuation riskMedium / highValuation relies heavily on long-term growth realization rather than near-term earnings support.
Competition risk (branded and generic ophthalmology competition)HighHarrow contends with entrenched pharmaceutical giants and alternative generic treatments in core eyecare segments.
Business qualityMediumWhile revenue growth and niche medical positioning are strong, bottom-line profitability remains unproven on a sustained basis.
Dividend incomeLow / noneIncome-focused investors receive no dividend yield from holding the common stock.
Execution riskHighSuccessful performance depends heavily on seamless product launches, sales force productivity, and integration of acquired assets.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.21B USD
Price to earnings Ratio -
1Y Target Price 62.25
Price to earnings Ratio -
1Y Target Price 62.25
Volume (30-day avg) 692.7K shares
Beta 0.17
52 Weeks Range 25.76 - 54.85
Updated Date 11/20/2026
52 Weeks Range 25.76 - 54.85
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.76

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
75.0%
Active BUY / eligible
9 / 12
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 1.44%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HROW receives a 4-star rating, supported by solid unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
HROW has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+70.6%) and strong cash generation (FCF margin 15.7%) are partially offset by weak profitability (net margin -1.9%).

Financial Health Rating

★★★★★
HROW's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 28.9%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is HROW's strongest growth driver at +170.2% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+36.4%, strong) and earnings growth (+70.6%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 61.7% and approximately 75.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 17.99% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 7.30%
Opaleye Management Inc 6.40%
Private Capital Management, LLC 4.26%
Vanguard Capital Management, LLC 3.78%
Deep Track Capital, LP 2.58%

Unit Economics (Per $1K Revenue)

★★★★★
HROW generates approximately $751 of gross profit, $142 of operating income, and $157 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: -198.09% (Tax Credit)

Quantitative Style Profile

★★★★★
HROW has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Branded PharmaceuticalsCommercial sales of FDA-approved proprietary ophthalmic medications such as VEVYE, IHEEZO, and TRIESENCE.This is the higher-margin, brand-building side of the business driven by direct promotion to eye-care specialists.
ImprimisRx CompoundingCustomized, ophthalmology-focused compounded pharmaceutical formulations dispensed directly to doctors and surgery centers.This segment serves as the operational engine, generating steady recurring customer relationships and broad distribution reach.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-09
When After Market
Estimate 0.13
Actual 0.12

Profitability

Profit Margin -9.39%
Operating Margin (TTM) -1.99%

Management Effectiveness

Return on Assets (TTM) -0.93%
Return on Equity (TTM) -75.47%

Valuation

Trailing PE -
Forward PE 62.89
Enterprise Value 1.43B
Price to Sales(TTM) 3.98
Enterprise Value 1.43B
Price to Sales(TTM) 3.98
Enterprise Value to Revenue 4.72
Enterprise Value to EBITDA 64.78
Shares Outstanding 37.53M
Shares Floating 28.28M
Shares Outstanding 37.53M
Shares Floating 28.28M
Percent Insiders 17.99
Percent Institutions 61.71

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.